Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A RANDOMIZED, CONTROLLED, DOSE-RANGING TRIAL OF SERTINDOLE IN PATIENTS WITH SCHIZOPHRENIA
Autore:
VANKAMMEN DP; MCEVOY JP; TARGUM SD; KARDATZKE D; SEBREE TB; ANDORN A; BAKER RW; SCHOOLER NR; BORISON RL; CASEY D; ERESHEFSKY L; FUNDERBERG L; HAMNER M; KARSON C; MARDER S; MCKINNEY W; SMALL JG; TAMMINGA C; TUASON V; VOLAVKA J; CHUNG L;
Indirizzi:
UNIV PITTSBURGH,SCH MED,DEPT PSYCHIAT,DEPT VET AFFAIRS MED CTR,7180 HIGHLAND DR PITTSBURGH PA 15206 JOHN UMSTEAD HOSP BUTNER NC 27509 CROZER CHESTER MED CTR UPLAND PA 00000 ABBOTT LABS,PSYCHOPHARMACOL VENTURE ABBOTT PK IL 60064
Titolo Testata:
Psychopharmacology
fascicolo: 1-2, volume: 124, anno: 1996,
pagine: 168 - 175
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANTIPSYCHOTIC-DRUGS; RECEPTORS; NEURONS; PROFILE; RATS;
Keywords:
SCHIZOPHRENIA; NEUROLEPTICS; SERTINDOLE; PLACEBO; EXTRAPYRAMIDAL SYMPTOMS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Physical, Chemical & Earth Sciences
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
D.P. Vankammen et al., "A RANDOMIZED, CONTROLLED, DOSE-RANGING TRIAL OF SERTINDOLE IN PATIENTS WITH SCHIZOPHRENIA", Psychopharmacology, 124(1-2), 1996, pp. 168-175

Abstract

Sertindole is a novel antipsychotic agent with high selectivity for the mesolimbic dopaminergic pathway and nanomolar affinities for dopamine D-2 serotonin 5-HT2 and norepinephrine NE(alpha 1) receptors. This 40-day randomized, placebo-controlled, dose-ranging multicenter study was designed to assess the effect of sertindole on previously neuroleptic-responsive, hospitalized schizophrenic patients (n=205). Sertindole doses began at 4 mg/day and were increased to 8, 12 or 20 mg/day. depending on randomization. Efficacy measures included the Positive and Negative Syndrome Scale (PANSS). Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression (CGI). Extrapyramidal symptoms (EPS) were assessed by movement rating scales, EPS-related adverse events, and use of anti-EPS medications. A dose-related improvement was observed for PANSS, BPRS, and CGI, with statistically significant mean differences (P<0.05) between placebo and 20-mg/day sertindole (decreases from baseline of -5.8 versus -16.9 for PANSS, -4.8 versus -10.4 for BPRS,respectively). The differences in CGI final improvement score betweenplacebo and 20-mg/day sertindole were 3.8 versus 2.9, respectively. EPS-related events were comparable in the placebo and sertindole groups. In conclusion, sertindole 20 mg/day was effective, well tolerated, and not associated with significant motor system abnormalities.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 08:26:22